SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1

• Published in: Emerging microbes & infections Vol. 13; no. 1; p. 2359004
• Main Authors: Wang, Qian, Guo, Yicheng, Schwanz, Logan T., Mellis, Ian A., Sun, Yiwei, Qu, Yiming, Urtecho, Guillaume, Valdez, Riccardo, Stoneman, Emily, Gordon, Aubree, Wang, Harris H., Ho, David D., Liu, Lihong
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis Ltd 01.12.2024; Taylor & Francis; Taylor & Francis Group
• Subjects: Angiotensin-Converting Enzyme 2 - genetics; Angiotensin-Converting Enzyme 2 - metabolism; Antibodies; Antibodies, Neutralizing - immunology; Antibodies, Viral - blood; Antibodies, Viral - immunology; BA.2.87.1; Cell Line; Chemical bonds; COVID-19; COVID-19 - immunology; COVID-19 - virology; Drug dosages; EG.5.1; Emerging and Re-Emerging Coronaviruses; Humans; Immune Evasion; Infections; Infectious diseases; JN.1; mRNA vaccines; Mutation; Neutralization Tests; polyclonal sera; mRNA vaccines; Proteins; Research Letter; SARS-CoV-2; SARS-CoV-2 - genetics; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - immunology; Surgeons; Viruses; COVID-19; EG.5.1; SARS-CoV-2; receptor engagement; JN.1; BA.2.87.1; antibody evasion; viral infectivity; polyclonal sera; mRNA vaccines

As SARS-CoV-2 continues to spread and mutate, tracking the viral evolutionary trajectory and understanding the functional consequences of its mutations remain crucial. Here, we characterized the antibody evasion, ACE2 receptor engagement, and viral infectivity of the highly mutated SARS-CoV-2 Omicro...